Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, Surbhi Malhotra‐Kumar, José Miguel Cisneros et al.|The Lancet Infectious Diseases|2024Cited by 98
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Galia Rahav et al.|Critical Care|2022Cited by 93
Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort StudyAlessia Savoldi, Matteo Morra, Alessandro Castelli et al.|Biomedicines|2022Cited by 4